Evonile Pharma shifts flagship brands to in-house sales

Evonile Pharma Limited is moving promotion and distribution of certain flagship brands in-house after terminating a partner agreement effective September 30, 2026, and plans a dedicated field force of more than 900 people to reach approximately 150,000 healthcare professionals across India. The change follows its July 2026 change in control and transfer of key trademarks.

Why is Evonile Pharma bringing brand promotion in-house?

Evonile Pharma is replacing a partner-led distribution model with direct promotion and distribution to gain commercial independence over pricing, promotion and product-lifecycle decisions. The company terminated its agreement with a pharmaceutical-company partner effective September 30, 2026, bringing the promotion and distribution of certain brands under its own platform. Management says the new approach is intended to establish direct relationships with prescribers and a single integrated distribution network with real-time visibility.

The shift follows the July 29, 2026 change in control, when WaveRise Investments Limited and ChrysCapital Fund X became promoters after the sale of 17,450,680 equity shares, equal to 70.68% of share capital. On the same date, trademarks for Voveran, Macalvit and Methergin were assigned to Evonile Pharma under a trademark assignment and licence deed. The company says these assignments give it direct control over commercialisation, pricing and lifecycle decisions for those franchises.

Evonile Pharma was renamed from October 1, 2026, after shareholder approval on September 24, 2026. Its operating model remains asset-light: it owns no manufacturing facilities, uses third-party contract manufacturers in Karnataka, Daman, Goa, Uttarakhand, Maharashtra and Sikkim, and has appointed more than 20 carrying and forwarding agents across more than 15 states. This means the commercial transition is focused on sales, distribution and brand management rather than building production capacity.

What does Evonile Pharma’s sales-force plan involve?

Evonile Pharma is building a field force of more than 900 members dedicated solely to its portfolio, with planned coverage of approximately 150,000 healthcare professionals nationwide. The company intends to use the force for ethical medico-marketing programmes, supported by sales-force analytics, tools and distribution models. Its stated geographic focus includes metro cities and tier-2 and tier-3 markets, where specialist franchises are described as under-penetrated relative to their potential.

Management acknowledges that the move will create a one-time transition cost in Fiscal 2027 and that the cost may extend over time because field-force expenses will exceed current costs. The stated trade-off is permanent ownership of the commercial route to prescribers and the ability to retain the commercial value of brands through an independent platform. Whether this produces the intended revenue effect will depend on execution of the direct model rather than on the announced headcount alone.

The commercial transition begins against a period of lower reported revenue and a loss in the six months ended September 30, 2026. Revenue from operations fell by Rs 18.02 crore from the corresponding six-month period a year earlier, while Evonile Pharma moved from a profit of Rs 51.84 crore to a loss of Rs 45.33 crore.

How have Evonile Pharma’s annual financial indicators changed?

Evonile Pharma reported Fiscal 2026 revenue from operations of Rs 354.33 crore, marginally below Rs 356.27 crore in Fiscal 2025, while operating profit increased to Rs 92.15 crore from Rs 89.23 crore. Accordingly, operating profit margin rose to 26.0% from 25.0%. The comparison shows a Rs 1.94 crore revenue decline but a Rs 2.92 crore increase in operating profit over the two financial years ended March 31.

Profit after tax moved in the other direction, declining to Rs 93.18 crore in Fiscal 2026 from Rs 100.90 crore in Fiscal 2025. The profit-after-tax margin decreased to 26.3% from 28.3%, while earnings before interest, tax, depreciation and amortisation increased to Rs 94.10 crore from Rs 91.42 crore. These reported results predate the September 30, 2026 end of the partner arrangement and the planned Fiscal 2027 transition costs.

Which new therapy areas is Evonile Pharma adding?

Evonile Pharma has entered cardiology by acquiring the Indian trademarks Minipress and Minipres relating to Minipress XL, a prazosin brand indicated for primary and secondary hypertension, resistant hypertension and benign prostatic hyperplasia. The company describes Minipress XL as having approximately 63% market share and revenue compound annual growth of 6.50%. It presents the acquisition as part of a plan to add brands in chronic therapy areas and to use its asset-light model for further deals.

Evonile Pharma also entered ophthalmology through an exclusive distribution and promotion agreement with Novartis Healthcare Private Limited dated September 8, 2026. The India agreement covers the retina products Accentrix, or ranibizumab, and Pagenax, or brolucizumab. Accentrix is indicated for conditions including wet age-related macular degeneration, diabetic macular oedema and diabetic retinopathy, while patent-protected Pagenax is indicated for wet age-related macular degeneration and diabetic macular oedema.

The additions sit alongside anchor areas of pain management, women’s health, wellness, neuroscience and transplant immunology. In transplant care, Evonile Pharma imports and distributes Myfortic and Simulect as exclusive distributor of Novartis Pharma Services AG under a distribution agreement connected with the change in control. Its portfolio strategy also calls for in-licensing and new launches in cardio-metabolic and specialty therapy, alongside mergers and acquisitions to add brands in cardiology, diabetes, neurology, ophthalmology and gynaecology.

What execution and regulatory issues should Evonile Pharma address?

Evonile Pharma must execute the sales-force buildout, transfer the affected brands into its direct network and manage the disclosed higher Fiscal 2027 field-force costs. Its stated plan combines geographic expansion with specialist engagement, but the letter of offer cautions that acquisitions and promotion or distribution agreements may not be integrated successfully or deliver anticipated benefits. The company has also said that pharmaceutical demand forecasting and limited product shelf life can lead to inventory write-offs.

The October 1, 2026 name change creates a separate regulatory task. Evonile Pharma is applying to relevant authorities to renew approvals under its new name and says it has received certain approvals but awaits others. Its business requires licences and permits for importing, selling, stocking and distributing pharmaceutical products, including approvals linked to the Central Drugs Standard Control Organization. Delays or failure to update approvals could restrict trading and distribution activities, according to the company.

Conclusion

Evonile Pharma is reshaping its commercial model around direct control of established brands, a proposed field force of more than 900 people and broader chronic and specialty therapy exposure. The September 2026 end of the partner agreement, the July 2026 trademark assignments and the cardiology and ophthalmology additions are linked parts of that strategy, while the first-half revenue decline and loss provide the current financial context.

The next point to watch is the Fiscal 2027 cost and operational impact of building the field force and integrating direct distribution. Management has also disclosed plans for therapy-aligned acquisitions, in-licensing and launches, while the pending regulatory approvals required after the October 1, 2026 name change remain an unresolved operational matter.